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Allergic bronchopulmonary aspergillosis (ABPA) is a Th2 hypersensitivity lung disease in response to Aspergillus fumigatus that
aﬀects asthmatic and cystic ﬁbrosis (CF) patients. Sensitization to A. fumigatus is common in both atopic asthmatic and CF
patients, yet only 1%–2% of asthmatic and 7%–9% of CF patients develop ABPA. ABPA is characterized by wheezing and
pulmonary inﬁltrates which may lead to pulmonary ﬁbrosis and/or bronchiectasis. The inﬂammatory response is characterized
by Th2 responses to Aspergillus allergens, increased serum IgE, and eosinophilia. A number of genetic risks have recently been
identiﬁedinthedevelopmentofABPA.TheseincludeHLA-DRandHLA-DQ,IL-4receptoralphachain(IL-4RA)polymorphisms,
IL-10 −1082GA promoter polymorphisms, surfactant protein A2 (SP-A2) polymorphisms, and cystic ﬁbrosis transmembrane
conductance regulator gene (CFTR) mutations. The studies indicate that ABPA patients are genetically at risk to develop skewed
and heightened Th2 responses to A. fumigatus antigens. These genetic risk studies and their consequences of elevated biologic
markers may aid in identifying asthmatic and CF patients who are at risk to the development of ABPA. Furthermore, these studies
suggestthatimmunemodulationwithmedicationssuchasanti-IgE,anti-IL-4,and/orIL-13monoclonalantibodiesmaybehelpful
in the treatment of ABPA.
1.Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is a hyper-
sensitivity lung disease due to bronchial colonization by
Aspergillus fumigatus that occurs in susceptible patients with
asthma and cystic ﬁbrosis (CF). The ﬁrst published descrip-
tion of ABPA as an entity came from the United Kingdom
in 1952 [1], while the ﬁrst cases in the United States were
reported a decade later [2, 3]. ABPA aﬀects approximately
1%–2% of asthmatic patients and 7%–9% of CF patients
[4–6]. If unrecognized or poorly treated, ABPA leads to air-
way destruction, bronchiectasis, and/or pulmonary ﬁbrosis,
resulting in signiﬁcant morbidity and mortality.
The diagnosis of ABPA is based on clinical and immuno-
logicreactivitytoA.fumigatus.Theminimalcriteriarequired
for the diagnosis of ABPA are: (1) asthma or cystic ﬁbrosis
with deterioration of lung function, for example, wheezing,
(2) immediate Aspergillus skin test reactivity, (3) total serum
IgE ≥ 1000IU/mL, (4) elevated Aspergillus speciﬁc IgE and
IgG antibodies, and (5) chest radiographic inﬁltrates. Addi-
tional criteria may include peripheral blood eosinophilia,
Aspergillus serum precipitating antibodies, central bronch-
iectasis, and Aspergillus containing mucus plug production
[7–11].ThedesignationofABPA-seropositive(ABPA-S)may
be used to classify asthmatic patients who meet the re-
quired criteria but lack the proximal or central bronchiec-
tasis (ABPA-CB). High-resolution computed tomography
(HRCT)maydemonstratecentralbronchiectasisintheinner
twothirdsoftheﬁeldevenintheabsenceofchestradiograph
lesions. The clinician should note that the development of
ABPA is not dependent on asthma severity. The diagnosis of
ABPA in CF is more complicated and disagreement exists in
the literature regarding the diagnostic criteria. The diﬃculty
lies in the fact that the usual criteria for ABPA and the com-
mon signs and symptoms of CF overlap. The most recent
Cystic Fibrosis Foundation Consensus Conference proposed
the following diagnostic criteria: (1) acute or subacute pul-
monary deterioration not attributable to another etiology,2 Journal of Allergy
(2) total serum IgE >1000IU/mL, (3) immediate cutaneous
reactivity to Aspergillus or in vitro speciﬁc IgE antibodies to
Aspergillus, and (4) one of the following: Aspergillus serum
precipitins, elevated speciﬁc IgG anti-Aspergillus antibodies,
new or recent chest radiographic, or chest CT abnormalities
that have not cleared with antibiotics and chest physiother-
apy [12].
1.1. Radiographic and Laboratory Investigations. There are
several characteristic radiographic abnormalities associated
with ABPA [7–11]. The most common lesion is a large,
homogeneous shadow in one of the upper lobes with no
change in volume. The shadow may be triangular, lobar, or
patchy, and it frequently moves to another site. “Tram-line”
shadows are ﬁne parallel lines radiating from the hila that
represent inﬂammation of airway walls. Mucoid impaction
causes toothpaste shadows or gloved-ﬁnger shadows, which
can be seen on plain radiograph.
Adult patients have been reported with normal chest ra-
diographs so radiographic abnormalities are not invariably
present. In these individuals, HRCT scan may reveal central
cylindrical bronchiectasis even in the absence of chest ra-
diograph abnormalities. Sometimes, “tree-in-bud pattern”
may been seen on HRCT scan that indicates some degree
of airway mucus plugging. It is more commonly considered
evidence of atypical mycobacterial infection and may be
seen in cystic ﬁbrosis. However, central bronchiectasis is a
common complication and ﬁnding in all CF patients.
Laboratory tests that support the diagnosis of ABPA are
those that demonstrate allergy to the A. fumigatus,s u c ha s
elevated speciﬁc IgE anti-Aspergillus antibodies and positive
Aspergillus precipitins [7–11]. Culture of A. fumigatus from
the sputum is only a secondary criterion for the diagnosis
of ABPA, because a large proportion of individuals with CF
without ABPA have Aspergillus on sputum cultures. Some
normal individuals and many individuals with lung diseases
have small numbers of spores in their sputum; these are
probably present because of passive inhalation. The presence
of hyphae is more speciﬁc, and the presence of eosinophils
in association with hyphal elements is suggestive of the
diagnosis. At the time of radiographic exacerbation, the
presence of eosinophilia in sputum or blood is suggestive of
ABPA in asthmatics and is a primary diagnostic criterion.
The peripheral blood eosinophil count is usually greater
than 1000/mm3, and values greater than 3000/mm3 are com-
mon. Eosinophilia is not a diagnostic criteria of ABPA in
CF patients. In the authors’ experience, eosinophilia is an
uncommon ﬁnding in CF ABPA patients.
An increased total serum IgE level is very characteristic
of ABPA, and values may reach as high as 30,000IU/mL.
Usually, the level is greater than 1000IU/mL. Much of the
IgE is not speciﬁc to Aspergillus but is the result of polyclonal
B-cell activation. The IgE level is a very useful marker of
disease activity, and it can be used to follow outpatients for
“ﬂares”. The simple skin-prick test is a useful screening test,
as ABPA is very unlikely in patients with a negative re-
action. A dual-reaction skin test with an immediate (10–
15 minutes) and a late (4–8 hours) reaction may occur
but is uncommon in ABPA. Alternatively, serum may be
measured for the presence of speciﬁc IgE and IgG antibodies.
Patients with Aspergillus-sensitive asthma will generally have
elevated Aspergillus-speciﬁc IgE antibodies, but patients with
ABPA will have much higher Aspergillus-speciﬁc IgE levels.
Hemmann et al. [13] reported that ABPA and Aspergillus-
sensitive patients have elevated IgE antibodies to recombi-
nant Aspergillus Asp f1, Asp f3, Asp f4, and Asp f6 allergens
and that IgE levels to Asp f4 and Asp f6 is highly speciﬁc for
ABPA in CF patients.
Diﬀerentiating between a bacterial ﬂare versus an ABPA
ﬂare in CF patients may be diﬃcult. A useful serum biologic
marker may be thymus and activation-regulated chemokine
(TARC) or CCL17. Latzin et al. [14] and Hartl et al. [15]
reported that TARC was elevated in CF patients with ABPA
and was further elevated during acute ﬂares of ABPA. TARC
is a chemokine whose ligand is CCR4 receptor on CD4+ Th2
cells.
In ABPA, immunoelectrophoresis generally shows one
to three precipitin lines, often to only one extract [7–11].
Patients with aspergilloma will have multiple precipitin lines
to all antigen extracts. Extracts of A. fumigatus contain a
complex mixture of proteins that are mainly derived from
the hyphae. Antigenic composition varies between batches
according to the culture conditions even within the same
laboratory. There is, therefore, a lack of standardization that
makes it diﬃcult to compare results between laboratories.
There are 22 recognized recombinant allergens by the Inter-
national Union of Immunological Societies. With puriﬁca-
tion of these major antigenic components, this may lead to
improved diagnosis.
1.2. Pulmonary Pathology of ABPA. The gross pathology of
ABPA demonstrates cylindrical bronchiectasis of the central
airways, particularly those to the upper lobes [7–11]. These
airwaysmaybeoccludedby“mucoidimpaction,”acondition
in which large airways are occluded by impacted mucus and
hyphae. Airway occlusion may lead to atelectasis of a seg-
ment or lobe and, if the atelectasis is long-standing, saccular
bronchiectasis may result. Typically, ABPA is worse in the
upper lobes than in the lower lobes. Microscopic exam-
ination of the airways shows inﬁltration of the airway wall
with eosinophils, lymphocytes, and plasma cells. The airway
lumen may be occluded by mucus containing hyphal ele-
ments and inﬂammatory cells, especially eosinophils. Squa-
mous metaplasia of the bronchial mucosa commonly devel-
ops, and granulomas may form. Rarely, bronchiolitis obliter-
ans or bronchocentric granulomatosis develops.
2. Immunopathogenesis of ABPA
As seen in Figure 1, the pathogenesis of ABPA in susceptible
personsbeginswiththeinhalationofA.fumigatussporesthat
germinate into hyphae deep within the bronchi. Fragments
of hyphae have also been found within the lung parenchyma,
potentially resulting in high concentrations of Aspergillus
allergens exposed to the respiratory epithelium and immune
system [16–19]. These allergens are processed by HLA-DR2
or HLA-DR5 bearing antigen presenting cells (APCs) and
presented to T cells within bronchoalveolar lymphoid tissueJournal of Allergy 3
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Figure 1: Proposed immunopathogenesis of ABPA. In the pathogenesis of ABPA, A. fumigatus proteases have a direct eﬀect on bronchial
epithelia causing epithelial cell damage with subsequent stimulation of cytokines and chemokines. Aspergillus proteins are processed via
HLA-DR2/DR5 bearing dendritic cells that skew the Th0 response to a Th2 response. Th2 cytokines stimulate IgE synthesis and eosinophil
activation. This leads to an eosinophilic inﬂammatory in the bronchial airways.
(BALT). The resulting CD4+ T cell responses to Aspergillus
are skewed toward Th2 response with the production of IL-
4, IL-5, and IL-13 cytokines.
2.1. Eﬀect of Aspergillus on Bronchial Epithelium. A. fumiga-
tus spores 3 to 5μm in size are inhaled and germinate deep
within the bronchi into hyphae [17]. In addition, fragments
of the hyphae can be identiﬁed within the interstitial of
the pulmonary parenchyma. The implication of this is that
there is the potential for high concentrations of A. fumigatus
allergens exposed to the respiratory epithelium and immune
system. A. fumigatus releases a variety of proteins, including
superoxide dismutases, catalases, proteases, ribotoxin, phos-
pholipases, hemolysin, gliotoxin, phthioic acid, and other
toxins. The ﬁrst line of defense against Aspergillus coloniza-
tion in the lungs is macrophage and neutrophil killing of
the conidia and the hyphae. In the development of ABPA,
Kauﬀman’s group proposed that Aspergillus proteins have a
direct eﬀect on the pulmonary epithelia and macrophage
inﬂammation [20, 21]. They demonstrated that Aspergillus
proteases induce epithelial cell detachment. In addition,
protease-containing culture ﬁltrates of Aspergillus induce
human bronchial cell lines to produce proinﬂammatory che-
mokinesandcytokines,suchasIL-8,IL-6,andMCP-1.Thus,
various Aspergillus proteins have signiﬁcant biologic activity
that disrupts the epithelial integrity and induces a monokine
inﬂammatory response. This protease activity is thought to
allow for enhanced allergen exposure to the bronchoalveolar
lymphoidtissueimmunesystem.Thisisevidentbythebron-
choalveolar lymphoid tissue synthesis of Aspergillus-speciﬁc
IgE and IgA antibodies.
An important pathogenic feature of Aspergillus and other
microbes is their ability to interact with epithelial cells on
the mucosal surface. Macrophage and neutrophil killing of
the conidia and hyphae is the ﬁrst line of defense against
colonizationinthelungs[12,22–24].Thisisevidencedbyan
increased susceptibility to invasive pulmonary aspergillosis
in patients with chronic granulomatous disease, a disorder
of phagocyte killing. A. fumigatus has several virulence
factors, including proteolytic enzymes that can interfere with
humoral and cellular defense in the airways [25, 26]. Pro-
teases from Aspergillus and other fungi, including Alternaria
and Cladosporium, have been shown to cause epithelial cell
detachmentthoughAspergillusproteasesdemonstratedmore
activity at lower concentrations [25–28].
In addition to damaging the integrity of the epithelial
cell layer, Kauﬀman’s group demonstrated that protease con-
taining culture inﬁltrates of A. fumigatus induced human
bronchial cell lines to produce proinﬂammatory chemokines
and cytokines, such as monocyte chemoattractant protein
(MCP)-1, IL-8, and IL-6 [20]. MCP-1 has been implicated in
directly stimulating the development of Th2 cells [29]. The
cytokine-release activity could be ascribed to the proteolytic
activities of these extracts [20, 27]. These observations
suggested that proteolytic enzymes released by Aspergillus,
growing on and between epithelial cells, were responsible for4 Journal of Allergy
the induction of chemoattractive cytokines by epithelial cells
and the corresponding inﬂammation. It was proposed that
the induction of the severe inﬂammatory responses by the
direct activation of epithelial cells may cause additional
harm to the epithelial cell layer [25]. Destruction of the
epithelial cell barrier either by fungal proteases or eosino-
philic and neutrophilic inﬂammation was followed by repair
mechanisms, resulting in the inﬂux of serum proteins and
extracellular matrix proteins to the luminal side of the
epithelium [30]. Because spores and mycelium of A. fumig-
atus have surface structures that are able to interact with
extracellular matrix molecules, damage and repair mecha-
nisms of the airway mucosa may facilitate the binding of
Aspergillus to the damaged sites of the airways. The enhanced
release of proteolytic enzymes and allergens on the epithelial
surface would induce a continuous inﬂammatory response
and mast cell degranulation, resulting in severe and long-
lasting periods of exacerbations of ABPA.
2.2. Aspergillus-Speciﬁc Th2 Cells. The immune response to
Aspergillus antigens in ABPA patients, as well as allergic
asthmatic and CF patients, is characterized by a Th2 CD4+
Tl y m p h o c y t er e s p o n s e[ 17, 31–35]. Skin test reactivity to
Aspergillus is found in 20%–25% of asthmatic patients [5,
36, 37] and 31%–59% of CF patients [13, 38]. Although
sensitization is common in these populations, only a small
percentage of patients develop ABPA.
S e v e r a lg r o u p sh a v eo b s e r v e dTc e l ll y m p h o p r o l i f e r a t i v e
responses to crude Aspergillus extracts [31, 39–41]. Subse-
quently, Aspergillus-speciﬁc T cell responses were examined
and shown to enhance B cell IgE synthesis [41]. In addition,
Asp f1 T cell lines were generated, and the phenotypes were
found to be CD4+ CD25+ T cells with the cytokine proﬁle
IL-4+ and IFNγ−, indicating Th2 CD4+ T cells [4]. Chauhan
et al. [42] subsequently developed T cell clones from asth-
matic ABPA patients and demonstrated either Th2 (IL-4+,
IFN-γ−) or Th0 (IL-4+,I F N - γ+) patterns. We demonstrated
that ABPA subjects have increased frequency of IL-4+ CD3+
T cells from Asp f2/f3/f4-stimulated peripheral blood lym-
phocytes compared to Aspergillus sensitive non-ABPA sub-
jects [4]. IL-4 produced by T lymphocytes binds to the IL-
4 receptor (IL-4R) on B cells and in association with the
CD40L/CD40 signals, results in IgE isotype switching and
B cell proliferation [43]. IL-4 also increases the expression
of CD86, which has been linked to eosinophilic airway in-
ﬂammation and airway hyperresponsiveness after allergen
challenge. A central question then is how ABPA patients
diﬀer from Aspergillus-sensitive atopic asthmatic and CF
patients. We hypothesize that ABPA develops in genetically
susceptible individuals with asthma and CF because of in-
creased frequency and/or activity of A. fumigatus-speciﬁc
Th2 CD4+ cells. We further propose that polymorphisms
of the interleukin-4 receptor alpha chain (IL-4RA) subunit
and HLA-DR2/DR5 are the genetic susceptibility risk factors
responsible for the development of ABPA.
2.3. IL-4 Responses in ABPA. Human studies and murine
models have shown that CD4+ Th2 cells and their cytokines
are central to the development of ABPA [4, 32–35, 39, 44].
In particular, IL-4 has a key role in the allergic inﬂammatory
response with eﬀects on various cell populations. Its func-
tions include increasing VCAM-1 expression on endothelial
cells, which enhances the recruitment of other immune cells,
particularly eosinophils, stimulating proliferation of ﬁbrob-
lasts, important in airway remodeling, and increasing Th2
diﬀerentiation while decreasing Th1 diﬀerentiation and the
productionofIFN-γ[45,46].IL-4alsohasamyriadofeﬀects
on B lymphocytes including the stimulation of growth and
activation, increasing HLA-DR class II expression important
for antigen presentation and inducing cell surface expression
of CD23 and soluble CD23. This cell surface molecule is the
low aﬃnity IgE receptor (FcεRII) and an activation marker
present on a number of cells including B cells, activated
T cells, monocytes, and eosinophils. CD23 plays a role in
augmenting B cell IgE synthesis through its interactions with
CD21 [47, 48]. Recently, in 2003, anti-CD23 monoclonal
antibody was administered to atopic asthmatic subjects and
resulted in decreased serum IgE levels [49]. In addition, IL-4
has a more direct role in IgE isotype switching by B-cells. It
shouldbenotedthatIL-13mayalsostimulatethesynthesisof
IgEandistheonlyothercytokinethathasthiscapability[50–
52]. Recently, in 2000 and 2004, increased sensitivity to in
vitroIL-4stimulationasmeasuredbyenhancedexpressionof
the low-aﬃnity IgE receptor (CD23) on B cells was observed
in ABPA patients [32, 33]. This was associated with single-
nucleotide polymorphisms of the IL-4 receptor alpha chain
(IL-4RA) in 92% of ABPA subjects, principally the IL-4-
binding single-nucleotide polymorphism ile75val [19, 34,
35]. This increased sensitivity to IL-4 is demonstrated by
increased expression of CD23 and CD86 on B cells of ABPA
subjects and increased CD23 expression during ﬂares of
ABPA [19]. CD23 is expressed on a variety of cells, including
B cells, natural killer cells, subpopulations of T cells, and
a subpopulation of dendritic cells. T-cell CD23 and B-cell
CD21 form a costimulatory pathway. T-cell CD28, B-cells
CD80, and CD86 costimulatory pathways activate both T
and B cells, and CD28:CD86 is important in IgE synthesis.
CD86 is also found on dendritic cells that have the histamine
receptor 2, which skews antigen-speciﬁc T cells to a Th2 re-
sponse. We have also observed increased CD86 expression
on monocyte-derived dendritic cells of ABPA subjects. Thus,
antigen-presenting cells such as monocytes and dendritic
cells bearing HLA-DR2 and/or HLA-DR5 and increased
sensitivity to IL-4 stimulation probably play a critical role in
skewing A. fumigatus-speciﬁc Th2 responses in ABPA.
3. Immunogenetics of ABPA
3.1. HLA-DR and HLA-DQ. HLA-DR restriction has been
shown to be a risk factor for the development of ABPA
(Table 1). Chauhan et al. [42, 53] observed that asthmatic
and CF patients who expressed HLA-DR2 and/or DR5 but
lacked HLA-DQ2 were at increased risk for ABPA after
exposure to A. fumigatus. Within HLA-DR2 and HLA-DR5,
there are restricted genotypes. In particular, HLA-DR2 HLA-
DRB1∗1501 and HLA-DRB1∗1503 genotypes were reported
to provide high relative risk. On the other hand, 40% to 44%
of non-ABPA atopic Aspergillus-sensitive individuals haveJournal of Allergy 5
Table 1: Genetic risk factors in the development of allergic bron-
chopulmonary aspergillosis.
(i) HLA-DR restriction and HLA-DQ protection
(a) HLA-DR2 restriction
HLA-DRB1∗1501 and ∗HLA-DRB1∗1503
(b) HLA-DR5
HLA-DRB1∗1104
(c) HLA-DQ2 protective, decreased in ABPA
DQB1∗0201
(ii) IL-4RA polymorphisms
(a) IL-4RA ile75val
(iii) IL-10 polymorphisms
(a) Promoter −1082 GG genotype
(iv) Surfactant protein A2 (SP-A2) polymorphisms
(a) SP-A2 ala91pro
(v) Cystic ﬁbrosis transmembrane conductance regulator
(CFTR) mutations
(a) Heterozygous CFTR mutations in asthmatic patients
with ABPA
(vi) Toll-like receptor (TLR) polymorphisms
(a) TLR9 T-1237C polymorphism
the HLA-DR2 and/or DR5 type. Further studies indicated
that the presence of HLA-DQ2, especially DQB1∗0201, pro-
vided protection from the development of ABPA. Further-
more, Chauhan et al. [42] demonstrated that Asp f l allergen
has a low-aﬃnity of binding to HLA-DR. This is consistent
withTh2Tcellresponsepreviouslyreportedbyothersinthat
strong antigen HLA-DR-Ag-TCR aﬃnity binding favored a
Th1 cellular response, whereas low aﬃnity binding favored a
Th2 humoral response [54–58]. Four major Vβ chains, Vβ 3,
6, 13, and 14, reacted to Asp f1.
3.2.IL-4AlphaChainReceptor(IL-4RA)Polymorphisms. The
IL-4 receptor is a type I cytokine receptor and exists as a
heterodimer that shares a subunit, IL-4 receptor alpha chain
(IL-4RA), with the IL-13 receptor alpha (IL-13RA) [59].
TherearetwotypesofIL-4receptors.TypeIreceptors,found
on all lymphohematopoietic cells, are composed of the IL-
4RA and the common gamma chain (γC), which is also a
component of IL-2, IL-7, IL-9, IL-15, and IL-21 cytokine
receptors [60]. IL-4 receptor type II, also known as the IL-
13 receptor, is formed by the association of IL-4RA with the
IL-13RA subunits and is located on immune cells, bronchial
epithelium, and vascular endothelium. IL-4 stimulates both
type I and type II receptors, while IL-13 signals through type
II receptors.
A potential gain-of-function in the IL-4RA subunit may
be responsible for B cell hyperreactivity in ABPA. As a
consequence of increased IL-4R activity, proinﬂammatory
cytokines skew T cell responses to a dominant Th2 pattern
which ultimately contributes to the pathophysiology and
progression of ABPA. There are eight naturally occurring
single nucleotide polymorphisms (SNPs) of the IL4RA
gene: ile75val, glu400ala, cys431arg, ser436leu, ser503pro,
gln576arg, ser752ala, and ser786pro reported thus far [61–
71]. Chromosome 16, which has been associated with
asthma, contains the IL-4RA gene [66]. Studies have iden-
tiﬁed a number of these SNPs to be associated with atopy
prevalence and asthma severity. In 1997, Hershey et al. [62]
initially reported on a high prevalence of atopy and a gain-
of-function in the IL-4RA as measured by increased CD23
expression in patients with gln576arg and a later study found
thatthisallelecorrelatedwithasthmaseverity[68].Hershey’s
group found that the presence of two variants, val75 and
arg576 together, resulted in elevated IL-4 dependent CD23
expression which was not observed when these SNPs were
present alone [71]. In our studies, the presence of the val75
allele, located within the IL-4 binding region, was found in
87.5% of ABPA subjects examined, while the cytoplasmic
SNPs were present much less frequently at 27.3% for ala400,
27.3% pro503, 27.3% arg576, and 9.1% arg431. Although
these alleles, particularly val75, appear to be common in the
general population, their high prevalence in ABPA suggests
that they may be a risk factor in the development of the
disease (Table 1).
3.3. IL-10 Polymorphisms. Brouard and coworkers [72]r e -
cently in 2005 reported another genetic risk, the association
of the −1082GG genotype of the IL-10 promoter with col-
onization with A. fumigatus and the development of ABPA
inCF(Table 1).The −1082GGpolymorphismhasbeenasso-
ciated with increased IL-10 synthesis, whereas the −1082A
allele has lower IL-10 synthesis. Thus, dendritic cells express-
ing HLA-DR2/DR5, increased IL-10 synthesis and increased
sensitivity to IL-4 stimulation due to IL-4RA polymor-
phisms, may be responsible for skewing Aspergillus-speciﬁc
Th2 responses in ABPA.
3.4. Surfactant Protein A2 (SP-A2) Polymorphisms. Recently,
in 2003, Saxena et al. [73] reported that ABPA patients
with polymorphisms (ala91pro and arg94arg) in the collagen
region of pulmonary surfactant protein A2 (SP-A2)h a d
more elevated total IgE levels and higher percentages of eos-
inophilia than observed in those patients who lacked the
SNPs (Table 1). They also found that 80% of patients
carrying both alleles had ABPA (P = 0.0079, OR = 10.4),
while only 50% and 60% of patients carrying each allele,
individually, were ABPA subjects, suggesting an additive ef-
fect. How these SNPs aﬀect SP-A has not yet been elucidated,
but the collagen region spanning both SNPs has been shown
to associate with receptors of alveolar macrophages [74],
which are important in protecting against Aspergillus colo-
nization [22]. It is theorized that changes in conformation
or aﬃnity of SP-A2 may decrease these interactions and
compromise host defense.
3.5. Cystic Fibrosis Transmembrane Conductance Regulator
(CFTR) Gene Mutations. B e c a u s eA B P Ai sf o u n di nh i g h e s t
incidence among atopic patients with CF, Miller et al. [75]
examined mutations in the cystic ﬁbrosis transmembrane
conductance regulator gene (CFTR) in subjects without CF
(Table 1). Their group reported that mutations were present
at a higher frequency in asthmatic patients who developed6 Journal of Allergy
ABPA, 6 of 21 (28.5%), versus control asthmatics, 2 of
43 (4.6%). These ABPA patients were heterozygous for the
mutations(1patientwascompoundheterozygoteandreclas-
siﬁed as atypical CF), did not have a clinical diagnosis of CF,
and had sweat chlorides <60mEq/L. Although the abnormal
airway mucus in CF is thought to be a susceptibility factor
for ABPA due to enhanced trapping of Aspergillus spores, it is
unclear what eﬀect heterozygous CFTR mutations may have
on mucus quality in asthmatic airways.
3.6. Toll-Like Receptor (TLR) Polymorphisms. Carvalho et al.
[76] examined Toll-like receptor (TLR) polymorphisms of
TLR2, TLR4, and TLR9 in cavitary pulmonary aspergillosis
(CCPA) and severe asthma associated with fungal sensi-
tization (SAFS). TLR-4 is among the major receptors for
Aspergillus hyphaeandplaysanimportantpartininnatehost
defense as TLR-4-deﬁcient mice have increased susceptibility
to invasive aspergillosis [77]. In CCPA patients, there was
signiﬁcantly increased frequency of the G allele of TLR4 on
asp299gly. ABPA patients had increased frequency of allele C
for the TLR9 T-1237C polymorphism compared to control
patients. However, in SAFS patients who are predominantly
Aspergillus sensitive, there was no association of polymor-
phisms of TLR2, TLR4,o rTLR9. TLR-9 is a receptor that
recognizes CpG motifs prevalent in bacterial and viral DNA.
Aspergillus hyphae and conidia do signal through TLR-9 on
murine neutrophils [78]. TLR-9-deﬁcient mice demonstrate
greater conidial and hyphal damage. In addition, Lazarus
et al. [79] reported that TLR9 polymorphisms have been
associated with increased risk of asthma. Novak et al.
[80] reported that the TLR9 C allele of T-1237C decreases
expression. Thus, decreased TLR-9 protective function may
be an underlying susceptibility in the development of ABPA.
4. Conclusions
The prognosis of ABPA is good if the disease is detected
early and treatment started promptly. It is important that the
diagnosis is made and treatment commenced before there
is permanent lung damage from bronchiectasis. In such pa-
tients, there should be no progression of the disease, al-
though relapses can occur many years later, and long-term
followup is recommended. In children with CF, the relapses
seem to be more frequent than they are in patients with
asthma, and careful surveillance is necessary to ensure res-
olution of the disease process. In some CF patients, it is
diﬃcult to wean the steroids without an increase in symp-
toms, such as dyspnea and wheezing, whether this is due
to the underlying CF lung disease or due to patients going
from stage II to stage III ABPA on withdrawal of steroids
is unclear. Adjunctive treatment with antifungal therapy to
Aspergillusshouldbeconsidered.Symptomsarenotareliable
guide to therapy; therefore, it is important to reevaluate the
chest radiograph and the serum IgE at regular intervals until
a long-term remission is established.
ABPA occurs with a worldwide distribution in a signiﬁ-
cant number of patients with CF and less frequently in those
with asthma. Early diagnosis and treatment are essential in
preventingend-stageprogression.ThedevelopmentofABPA
is probably the combination of many genetic susceptibility
factors, gene-gene interactions, and environmental exposure
which work together. Understanding of the genetic risks and
immunopathogenesis of ABPA hopefully will lead to im-
proved early diagnosis and improved treatment of ABPA.
Abbreviations
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